PharmaEssentia Appoints Beth A. Krewson as Head of Legal
2024年7月22日 - 11:00PM
ビジネスワイヤ(英語)
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia
Corporation (TWSE: 6446), a global biopharmaceutical innovator
based in Taiwan leveraging deep expertise and proven scientific
principles to deliver new biologics in hematology and oncology,
today announced the appointment of Beth A. Krewson as Head of
Legal.
Krewson is a legal and compliance leader in the life sciences
industry with more than 20 years of experience, having served as an
executive, counselor and business partner to company leaders and
Boards of Directors. Her expertise spans legal, intellectual
property (IP), business development, corporate governance and
compliance matters. As Head of Legal, Krewson will be responsible
for PharmaEssentia USA’s legal and compliance strategy to advance
its leadership in myeloproliferative neoplasms (MPNs) and other
hematological diseases.
“Beth is a respected executive attorney with a successful track
record of building strong legal and compliance functions,
supporting product development and launches and negotiating
transactions,” said Dr. Ko-Chung Lin, PharmaEssentia Founder and
Chief Executive Officer. “As PharmaEssentia continues to grow as a
company, Beth’s integrity, creativity and expertise will enable us
to further our mission to innovate for patients with MPNs who are
in need of effective treatment options."
Prior to joining PharmaEssentia, Krewson served as the first
in-house General Counsel at Formation Bio, where she empowered a
legal and compliance team, oversaw patent strategy and an IP
portfolio and advised senior management on corporate, clinical,
manufacturing, finance, employment and contract matters. Before
Formation Bio, Krewson was the Senior Vice President, General
Counsel & Compliance Officer at BlueRock Therapeutics LP, where
she built an integrated legal, IP and compliance function to
support BlueRock’s business relationship with its parent company.
While at BlueRock, she also served as secretary to the Board of
Directors and advised the executive committee and senior management
on matters of diverse legal, regulatory, compliance and commercial
matters. Previously, she held General Counsel & Chief
Compliance Officer positions at Innocoll Biotherapeutics N.A. Inc.
and Churchill Pharmaceuticals LLC, as well as senior legal and
compliance positions at Incyte Corporation, Celgene Corporation and
GlaxoSmithKline.
Krewson received her J.D. from Suffolk University Law School and
is a U.S. Patent and Trademark Office (USPTO) Registered Attorney
with law licenses in Maryland, Washington, D.C. and Pennsylvania.
Her appointment expands the PharmaEssentia U.S. leadership team,
following the recent hiring of Fred Paster as Head of Commercial
and promotion of Dr. Robert Geller to General Manager.
About PharmaEssentia
PharmaEssentia (TPEx: 6446), headquartered in Taipei, Taiwan, is
a global and rapidly growing biopharmaceutical innovator.
Leveraging deep expertise and proven scientific principles,
PharmaEssentia aims to deliver effective new biologics for
challenging diseases in the areas of hematology, oncology, and
immunology with one approved product and a diversified pipeline.
Founded in 2003 by a team of Taiwanese-American executives and
renowned scientists from U.S. biotechnology and pharmaceutical
companies, today PharmaEssentia is expanding its global presence
with operations in the U.S., Japan, China, and Korea, along with a
world-class biologics production facility in Taichung, Taiwan.
For more information about PharmaEssentia USA, visit our
website, LinkedIn or Twitter.
Forward Looking Statement
This press release may contain forward looking statements,
including statements regarding the clinical benefits to be derived
from ropeginterferon alfa-2b, the commercial opportunity and
competitive positioning, new indications or labeling for
ropeginterferon alfa-2b, and business prospects for ropeginterferon
alfa-2b. For those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 and similar legislation
and regulations under Taiwanese law. These forward-looking
statements are based on management expectations and assumptions as
of the date of this press release, and actual results may differ
materially from those in these forward looking statements as a
result of various factors. These factors include whether BESREMi is
successfully commercialized and adopted by physicians and patients,
the extent to which reimbursement is available for BESREMi, and the
ability to receive FDA and other regulatory approvals for
additional indications for BESREMi. We do not undertake to update
any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof.
© 2024 PharmaEssentia Corporation. All rights reserved.
PharmaEssentia, the PharmaEssentia logo, and BESREMi are
trademarks or registered trademarks of PharmaEssentia
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240722450135/en/
Media Contacts: Muriel Huang,
muriel_huang@pharmaessentia.com